Abstract
Apolipoprotein J (apoJ) has been found associated with soluble amyloid beta (sA beta) in plasma and cerebrospinal fluid in normal individuals and co-deposited with fibrillar A beta in Alzheimer's cerebrovascular and parenchymal lesions. Although studies in vitro and in vivo indicate that apoJ is a major carrier protein for sA beta, its role in the fibrillogenesis process is not known. We report herein that apoJ in its native high-density lipoprotein lipidic environment is fully active to interact with A beta peptides. Furthermore, apoJ prevents aggregation and polymerization of synthetic A beta in vitro. The interaction was stable for at least 14 days at 37 degrees C in physiologic buffers, and the peptide retrieved after complex dissociation at low pH retained its inherent aggregation properties. In addition, the binding to apoJ protects synthetic A beta from proteolytic degradation; both A beta 1-42 and A beta 1-40 were more resistant to proteolysis by trypsin and chymotrypsin when complexed to apoJ. The data suggest that the interaction may preclude sA beta aggregation in biological fluids and point to a protecting role of apoJ for complexed A beta species.
Full Text
The Full Text of this article is available as a PDF (505.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barrow C. J., Yasuda A., Kenny P. T., Zagorski M. G. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol. 1992 Jun 20;225(4):1075–1093. doi: 10.1016/0022-2836(92)90106-t. [DOI] [PubMed] [Google Scholar]
- Bryan J. K. Molecular weights of protein multimers from polyacrylamide gel electrophoresis. Anal Biochem. 1977 Apr;78(2):513–519. doi: 10.1016/0003-2697(77)90111-7. [DOI] [PubMed] [Google Scholar]
- Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem. 1992 Jan 5;267(1):546–554. [PubMed] [Google Scholar]
- Busciglio J., Gabuzda D. H., Matsudaira P., Yankner B. A. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2092–2096. doi: 10.1073/pnas.90.5.2092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Castano E. M., Prelli F., Wisniewski T., Golabek A., Kumar R. A., Soto C., Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J. 1995 Mar 1;306(Pt 2):599–604. doi: 10.1042/bj3060599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Castaño E. M., Frangione B. Alzheimer's disease from the perspective of the systemic and localized forms of amyloidosis. Brain Pathol. 1991 Jul;1(4):263–271. doi: 10.1111/j.1750-3639.1991.tb00669.x. [DOI] [PubMed] [Google Scholar]
- Choi-Miura N. H., Sakamoto T., Ohtaki S., Nakamura H., Ishizawa S., Takagi Y., Gomi K., Tomita M. Elevated complement activities of sera from patients with high density lipoprotein deficiency (Tangier disease): the presence of normal level of clusterin and the possible implication in the atherosclerosis. Clin Exp Immunol. 1993 Aug;93(2):242–247. doi: 10.1111/j.1365-2249.1993.tb07973.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Choi N. H., Tobe T., Hara K., Yoshida H., Tomita M. Sandwich ELISA assay for quantitative measurement of SP-40,40 in seminal plasma and serum. J Immunol Methods. 1990 Aug 7;131(2):159–163. doi: 10.1016/0022-1759(90)90186-y. [DOI] [PubMed] [Google Scholar]
- Ghiso J., Matsubara E., Koudinov A., Choi-Miura N. H., Tomita M., Wisniewski T., Frangione B. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J. 1993 Jul 1;293(Pt 1):27–30. doi: 10.1042/bj2930027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Golabek A., Marques M. A., Lalowski M., Wisniewski T. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett. 1995 May 19;191(1-2):79–82. doi: 10.1016/0304-3940(95)11565-7. [DOI] [PubMed] [Google Scholar]
- Hilbich C., Kisters-Woike B., Reed J., Masters C. L., Beyreuther K. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J Mol Biol. 1991 Mar 5;218(1):149–163. doi: 10.1016/0022-2836(91)90881-6. [DOI] [PubMed] [Google Scholar]
- Hilbich C., Kisters-Woike B., Reed J., Masters C. L., Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol Biol. 1992 Nov 20;228(2):460–473. doi: 10.1016/0022-2836(92)90835-8. [DOI] [PubMed] [Google Scholar]
- Jenne D. E., Lowin B., Peitsch M. C., Böttcher A., Schmitz G., Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem. 1991 Jun 15;266(17):11030–11036. [PubMed] [Google Scholar]
- Koudinov A., Matsubara E., Frangione B., Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1164–1171. doi: 10.1006/bbrc.1994.2788. [DOI] [PubMed] [Google Scholar]
- Kounnas M. Z., Loukinova E. B., Stefansson S., Harmony J. A., Brewer B. H., Strickland D. K., Argraves W. S. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J Biol Chem. 1995 Jun 2;270(22):13070–13075. doi: 10.1074/jbc.270.22.13070. [DOI] [PubMed] [Google Scholar]
- Ma J., Yee A., Brewer H. B., Jr, Das S., Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994 Nov 3;372(6501):92–94. doi: 10.1038/372092a0. [DOI] [PubMed] [Google Scholar]
- Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245–4249. doi: 10.1073/pnas.82.12.4245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Matsubara E., Frangione B., Ghiso J. Characterization of apolipoprotein J-Alzheimer's A beta interaction. J Biol Chem. 1995 Mar 31;270(13):7563–7567. doi: 10.1074/jbc.270.13.7563. [DOI] [PubMed] [Google Scholar]
- Perczel A., Park K., Fasman G. D. Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: a practical guide. Anal Biochem. 1992 May 15;203(1):83–93. doi: 10.1016/0003-2697(92)90046-a. [DOI] [PubMed] [Google Scholar]
- Prelli F., Castaño E., Glenner G. G., Frangione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem. 1988 Aug;51(2):648–651. doi: 10.1111/j.1471-4159.1988.tb01087.x. [DOI] [PubMed] [Google Scholar]
- Saito A., Pietromonaco S., Loo A. K., Farquhar M. G. Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9725–9729. doi: 10.1073/pnas.91.21.9725. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sanan D. A., Weisgraber K. H., Russell S. J., Mahley R. W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A. D. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994 Aug;94(2):860–869. doi: 10.1172/JCI117407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schwarzman A. L., Gregori L., Vitek M. P., Lyubski S., Strittmatter W. J., Enghilde J. J., Bhasin R., Silverman J., Weisgraber K. H., Coyle P. K. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8368–8372. doi: 10.1073/pnas.91.18.8368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Selkoe D. J., Abraham C. R., Podlisny M. B., Duffy L. K. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem. 1986 Jun;46(6):1820–1834. doi: 10.1111/j.1471-4159.1986.tb08501.x. [DOI] [PubMed] [Google Scholar]
- Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992 Sep 24;359(6393):325–327. doi: 10.1038/359325a0. [DOI] [PubMed] [Google Scholar]
- Snyder S. W., Ladror U. S., Wade W. S., Wang G. T., Barrett L. W., Matayoshi E. D., Huffaker H. J., Krafft G. A., Holzman T. F. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J. 1994 Sep;67(3):1216–1228. doi: 10.1016/S0006-3495(94)80591-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977–1981. doi: 10.1073/pnas.90.5.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D. B. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993 Nov;61(5):1965–1968. doi: 10.1111/j.1471-4159.1993.tb09841.x. [DOI] [PubMed] [Google Scholar]
- Wisniewski T., Castano E., Ghiso J., Frangione B. Cerebrospinal fluid inhibits Alzheimer beta-amyloid fibril formation in vitro. Ann Neurol. 1993 Oct;34(4):631–633. doi: 10.1002/ana.410340422. [DOI] [PubMed] [Google Scholar]
- Wisniewski T., Castaño E. M., Golabek A., Vogel T., Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994 Nov;145(5):1030–1035. [PMC free article] [PubMed] [Google Scholar]
- Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992 Feb 3;135(2):235–238. doi: 10.1016/0304-3940(92)90444-c. [DOI] [PubMed] [Google Scholar]
- Wisniewski T., Ghiso J., Frangione B. Alzheimer's disease and soluble A beta. Neurobiol Aging. 1994 Mar-Apr;15(2):143–152. doi: 10.1016/0197-4580(94)90105-8. [DOI] [PubMed] [Google Scholar]
- Wisniewski T., Lalowski M., Levy E., Marques M. R., Frangione B. The amino acid sequence of neuritic plaque amyloid from a familial Alzheimer's disease patient. Ann Neurol. 1994 Feb;35(2):245–246. doi: 10.1002/ana.410350223. [DOI] [PubMed] [Google Scholar]
- Zlokovic B. V., Ghiso J., Mackic J. B., McComb J. G., Weiss M. H., Frangione B. Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1034–1040. doi: 10.1006/bbrc.1993.2582. [DOI] [PubMed] [Google Scholar]
- Zlokovic B. V., Martel C. L., Mackic J. B., Matsubara E., Wisniewski T., McComb J. G., Frangione B., Ghiso J. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1431–1437. doi: 10.1006/bbrc.1994.2825. [DOI] [PubMed] [Google Scholar]
- Zlokovic B. V., Martel C. L., Matsubara E., McComb J. G., Zheng G., McCluskey R. T., Frangione B., Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4229–4234. doi: 10.1073/pnas.93.9.4229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Silva H. V., Stuart W. D., Duvic C. R., Wetterau J. R., Ray M. J., Ferguson D. G., Albers H. W., Smith W. R., Harmony J. A. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem. 1990 Aug 5;265(22):13240–13247. [PubMed] [Google Scholar]